Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity

Posted on
intratumoral-delivery-of-flt3l-with-cxcr3/ccr5-ligands-promotes-xcr1+-cdc1-infiltration-and-activates-anti-tumor-immunity
Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity

Data availability

Data supporting the findings of this study are available within the article, Supplementary Information or Source data file. Source data are provided as a Source data file. Source data are provided with this paper.

References

  1. Pittet, M. J., Di Pilato, M., Garris, C. & Mempel, T. R. Dendritic cells as shepherds of T cell immunity in cancer. Immunity 56, 2218–2230 (2023).

    Google Scholar 

  2. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

    Google Scholar 

  3. Bosteels, V. & Janssens, S. Striking a balance: new perspectives on homeostatic dendritic cell maturation. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-024-01079-5 (2024).

  4. Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498–1512 (2019).

    Google Scholar 

  5. Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723 (2017).

    Google Scholar 

  6. Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498–1515 (2023).

    Google Scholar 

  7. Di Pilato, M. et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell 184, 4512–4530 (2021).

    Google Scholar 

  8. Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623–1642 (2021).

    Google Scholar 

  9. Fridman, W. H. et al. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity 56, 2254–2269 (2023).

    Google Scholar 

  10. Chen, J. H. et al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat. Immunol. 25, 644–658 (2024).

    Google Scholar 

  11. Magen, A. et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389–1399 (2023).

    Google Scholar 

  12. Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8a+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008).

  13. Sánchez-Paulete, A. R. et al. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant Semliki forest virus-derived vectors fosters dendritic cell-mediated T-cell cross-priming. Cancer Res. 78, 6643–6654 (2018).

    Google Scholar 

  14. Salmon, H. et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924–938 (2016).

    Google Scholar 

  15. Barry, K. C. et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat. Med. https://doi.org/10.1038/s41591-018-0085-8 (2018).

  16. Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).

    Google Scholar 

  17. Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity 54, 2338–2353.e6 (2021).

    Google Scholar 

  18. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).

    Google Scholar 

  19. Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).

    Google Scholar 

  20. Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289–307 (2020).

    Google Scholar 

  21. Böttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037 (2018).

    Google Scholar 

  22. Cabeza-Cabrerizo, M. et al. Recruitment of dendritic cell progenitors to foci of influenza A virus infection sustains immunity. Sci. Immunol. 6, eabi9331 (2021).

    Google Scholar 

  23. McKenna, H. J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489–3497 (2000).

    Google Scholar 

  24. Waskow, C. et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9, 676–683 (2008).

    Google Scholar 

  25. Momenilandi, M. et al. FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell 187, 2817–2837 (2024).

    Google Scholar 

  26. Cabeza-Cabrerizo, M. et al. Tissue clonality of dendritic cell subsets and emergency DCpoiesis revealed by multicolor fate mapping of DC progenitors. Sci. Immunol. 4, eaaw1941 (2019).

    Google Scholar 

  27. Guermonprez, P. et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat. Med. 19, 730–738 (2013).

    Google Scholar 

  28. Kapoor, V. N. et al. Gremlin 1+ fibroblastic niche maintains dendritic cell homeostasis in lymphoid tissues. Nat. Immunol. 22, 571–585 (2021).

    Google Scholar 

  29. Wu, S. Z. et al. Fibroblastic FLT3L supports lymph node dendritic cells in the interfollicular niche. Nat. Immunol. 26, 2170–2184 (2025).

  30. Saito, Y., Boddupalli, C. S., Borsotti, C. & Manz, M. G. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses. Eur. J. Immunol. 43, 1651–1658 (2013).

    Google Scholar 

  31. Lee, J. et al. Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. J. Exp. Med. 212, 385–399 (2015).

    Google Scholar 

  32. Clappaert, E. J. et al. Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models. Front. Immunol. 14, 1166180 (2023).

  33. Darrasse-Jèze, G. et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med. 206, 1853–1862 (2009).

    Google Scholar 

  34. Swee, L. K., Bosco, N., Malissen, B., Ceredig, R. & Rolink, A. Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood 113, 6277–6287 (2009).

    Google Scholar 

  35. Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).

    Google Scholar 

  36. Anselmi, G. et al. Engineered niches support the development of human dendritic cells in humanized mice. Nat. Commun. 11, 2054 (2020).

    Google Scholar 

  37. Blake, S. J. et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep. Med. 2, 100464 (2021).

    Google Scholar 

  38. Siwicki, M. et al. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci. Immunol. 6, eabi7083 (2021).

    Google Scholar 

  39. Salomon, R. et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat. Cancer 3, 287–302 (2022).

    Google Scholar 

  40. Mattiuz, R. et al. Novel cre-expressing mouse strains permitting to selectively track and edit type 1 conventional dendritic cells facilitate disentangling their complexity in vivo. Front. Immunol. 9, 2805 (2018).

    Google Scholar 

  41. Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018).

    Google Scholar 

  42. Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells. Immunity 50, 181–194 (2019).

    Google Scholar 

  43. Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211 (2019).

    Google Scholar 

  44. Ogilvie, P., Bardi, G., Clark-Lewis, I., Baggiolini, M. & Uguccioni, M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 97, 1920–1924 (2001).

    Google Scholar 

  45. Cook, S. J. et al. Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2. Immunol. Cell Biol. 96, 1131–1139 (2018).

    Google Scholar 

  46. Dangaj, D. et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35, 885–900 (2019).

    Google Scholar 

  47. Legrand, N. et al. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer-(NK) cell homeostasis in vivo. Proc. Natl. Acad. Sci. USA 108, 13224–13229 (2011).

    Google Scholar 

  48. Li, Y. et al. A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development. Eur. J. Immunol. 46, 1291–1299 (2016).

    Google Scholar 

  49. Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814–824 (2019).

    Google Scholar 

  50. Oba, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat. Commun. 11, 5415 (2020).

    Google Scholar 

  51. Lai, J. et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat. Immunol. 21, 914–926 (2020).

    Google Scholar 

  52. Wan, D. et al. Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation. Mol. Ther. Oncol. 33, 200975 (2025).

    Google Scholar 

  53. Stagg, J., Lejeune, L., Paquin, A. & Galipeau, J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum. Gene Ther. 15, 597–608 (2004).

    Google Scholar 

  54. Bae, J. et al. IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer. Nat. Cell Biol. 24, 1754–1765 (2022).

    Google Scholar 

  55. Ryu, C. H. et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum. Gene Ther. 22, 733–743 (2011).

    Google Scholar 

  56. Choi, S. H. et al. Tumor resection recruits effector T cells and boosts therapeutic efficacy of encapsulated stem cells expressing IFNβ in glioblastomas. Clin. Cancer Res. 23, 7047–7058 (2017).

    Google Scholar 

  57. Kułach, N. et al. Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma. Sci. Rep. 11, 18335 (2021).

    Google Scholar 

  58. Zhang, T. et al. Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity. Oncogene 41, 1866–1881 (2022).

    Google Scholar 

  59. Ren, C. et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther. 15, 1446–1453 (2008).

    Google Scholar 

  60. Villani, A.-C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).

    Google Scholar 

  61. See, P. et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science 356, eaag3009 (2017).

    Google Scholar 

  62. Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).

    Google Scholar 

  63. Mattiuz, R. et al. Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer. Preprint at bioRxiv https://doi.org/10.1101/2024.12.27.628014(2024).

  64. Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49, 1148–1161 (2018).

    Google Scholar 

  65. Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).

    Google Scholar 

  66. Liu, B. et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat. Cancer 3, 108–121 (2022).

    Google Scholar 

  67. Kidd, S. et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27, 2614–2623 (2009).

    Google Scholar 

  68. Kalimuthu, S. et al. In vivo tracking of chemokine receptor CXCR4-engineered mesenchymal stem cell migration by optical molecular imaging. Stem Cells Int. 2017, 8085637 (2017).

    Google Scholar 

  69. Pereboeva, L. & Curiel, D. T. Cellular vehicles for cancer gene therapy. BioDrugs 18, 361–385 (2004).

    Google Scholar 

  70. Hakkarainen, T. et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther. 18, 627–641 (2007).

    Google Scholar 

  71. Du, W. et al. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc. Natl. Acad. Sci. USA 114, E6157–E6165 (2017).

    Google Scholar 

  72. Josiah, D. T. et al. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol. Ther. 18, 377–385 (2010).

    Google Scholar 

  73. Kazimirsky, G., Jiang, W., Slavin, S., Ziv-Av, A. & Brodie, C. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res. Ther. 7, 149 (2016).

    Google Scholar 

  74. Yoon, A.-R. et al. Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res. 79, 4503–4514 (2019).

    Google Scholar 

  75. Sonabend, A. M. et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26, 831–841 (2008).

    Google Scholar 

  76. Svensson-Arvelund, J. et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat. Commun. 13, 7149 (2022).

    Google Scholar 

  77. Voehringer, D., Liang, H.-E. & Locksley, R. M. Homeostasis and effector function of lymphopenia-induced “memory-like” T cells in constitutively T cell-depleted mice. J. Immunol. 180, 4742–4753 (2008).

    Google Scholar 

  78. Bourdely, P. et al. Transcriptional and functional analysis of CD1c+ human dendritic cells identifies a CD163+ subset priming CD8+CD103+ T cells. Immunity 53, 335–352 (2020).

    Google Scholar 

  79. Laforêts, F., Donnadieu, E. & Balkwill, F. Protocol for real-time monitoring of CD8+ T and myeloid cell behavior in human high-grade serous ovarian cancer slices. STAR Protoc. 5, 103102 (2024).

    Google Scholar 

Download references

Acknowledgements

P.G. is a CNRS investigator (Centre National de la Recherche Scientifique). This work was supported by Fonds National Suisse (SINGERGIA SNF CRSII5_202246/1, P.G., S.H.), INSERM transfert CO-POC grant (P.G.), Agence Nationale pour la Recherche (ANR-17-CE11-0001-01 and ANR-18-IDEX-0001, P.G.), La Ligue contre le cancer (P.G.), Institut National du Cancer INCA (PL-BIO22-147, P.G.), Fondation pour la Recherche Médicale (EQU202203014687, P.G.), Fondation pour la Recherche sur le Cancer ARC (PJA2021060003913, P.G.) and the Pasteur Institute. We would like to thank the staff of the flow cytometry and the animal facility platforms from the CRI (Centre de Recherche sur l’Inflammation, Faculté de Médecine, Bichat) and from the Pasteur Institute for all the work, help and support in most of the experiments presented in this paper. We also like to thank the staff from the histopathology core facility from the Pasteur Institute for the liver H&E images. We thank Rémy Yim (Human Disease Models Core Facility, Institut Pasteur, Université Paris Cité, 75015 Paris, France), the Human Disease Models Core Facility (Institut Pasteur, Paris) and the CRB-Banque de Sang de Cordon, AP-HP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire, Paris, France for the experiments on the BRGSF reconstituted mice. We thank the units U1149 and U1016 of Institut National de la Santé et de la Recherche Médicale. We thank the unit UMR3738 of the Centre National de la Recherche at the Pasteur Institute. We also would like to thank Laleh Majlessi for providing the NanoLuciferase vector, Alexandre Boissonnas (Sorbonne Université, INSERM U1135, CNRS, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris 75013, France), Dr. Philippe Bousso (Dynamics of Immune Responses Unit, Institut Pasteur, Université de Paris Cité, INSERM U1223, F-75015 Paris, France), Loredana Saveanu and Dr. Laurie Menger (Inserm U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France) for providing us various cell lines, Marc Dalod, Dr. Tessa Bergsbaken (Department of Pathology, Immunology and Laboratory Medicine, Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Rutgers-The State University of New Jersey, Newark, NJ) and Dr. Sebastian Amigorena (Institut Curie, PSL University, INSERM U932, Immunity and Cancer, Paris, France) for providing us mice strains and Dr. Geneviève Marcelin (Sorbonne Université, INSERM U1269, Nutrition and obesities: systemic approach research group, Nutriomics, Paris F-75013, France) for providing us protocols.

Author information

Author notes

  1. These authors contributed equally: Louise Gorline, Fillipe Luiz Rosa do Carmo.

Authors and Affiliations

  1. Dendritic Cells and Adaptive Immunity Unit, Immunology Department, Institut Pasteur, Université de Paris Cité, Paris, France

    Louise Gorline, Fillipe Luiz Rosa do Carmo, Jérémie Bornères, Nathan Vaudiau, Aurélie Semervil, Aboubacar Sidiki K Coulibaly, Natacha Jugniot, Ikrame Haddar & Pierre Guermonprez

  2. CNRS UMR3738, Developmental Biology and Stem Cells, Institut Pasteur, Université de Paris Cité, Paris, France

    Louise Gorline, Fillipe Luiz Rosa do Carmo, Jérémie Bornères, Nathan Vaudiau, Aurélie Semervil, Aboubacar Sidiki K Coulibaly, Natacha Jugniot, Ikrame Haddar & Pierre Guermonprez

  3. Centre for Vaccine and Immunotherapy, Institut Pasteur, Paris, France

    Louise Gorline, Fillipe Luiz Rosa do Carmo, Jérémie Bornères, Nathan Vaudiau, Aurélie Semervil, Aboubacar Sidiki K Coulibaly, Natacha Jugniot, Ikrame Haddar, James P. Di Santo & Pierre Guermonprez

  4. Laboratory of Tumor Inflammation and Angiogenesis, Center for Cancer Biology, VIB, Leuven, Belgium

    Pierre Bourdely

  5. INSERM UMR 1016, CNRS UMR 8104, Institut Cochin, Université Paris Cité, Paris, France

    Pierre Bourdely, Aurélie Semervil, Zeina Abou Nader, Judith Weber & Julie Helft

  6. Bichat Medical School, INSERM UMR1149, CNRS EMR8252, Université Paris Cité, Paris, France

    Mathias Vetillard, Agathe Ok & Loredana Saveanu

  7. Department of Pathology and Immunology, Geneva Medical School, Geneva, Switzerland

    Mathilde Bausart, Flavia Fico & Stéphanie Hugues

  8. Human Disease Models Core Facility, Institut Pasteur, Université Paris Cité, Paris, France

    Oriane Fiquet, Marine Andrade & Mathilde Dusseaux

  9. Nutrition and Obesity: Systemic Approaches, Inserm, Sorbonne University, Paris, France

    Dicken Fardol & Emmanuel L. Gautier

  10. Inserm U1015, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France

    Hannah Theobald & Florent Ginhoux

  11. Inserm Transfert, Paris, France

    Matthieu Collin & Joseph Calmette

  12. Deparment of Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

    Giorgio Anselmi

  13. Virology Department, Pasteur-TheraVectys Joint Laboratory, Institut Pasteur, Université Paris Cité, Paris, France

    Laleh Majlessi

  14. Centre d’Immunologie de Marseille-Luminy, CIML, CNRS, INSERM, Aix Marseille Université, Marseille, France

    Marc Dalod

  15. Immunology Department, Immunité Innée, Institut Pasteur, Paris, France

    James P. Di Santo

Authors

  1. Louise Gorline
  2. Fillipe Luiz Rosa do Carmo
  3. Pierre Bourdely
  4. Jérémie Bornères
  5. Nathan Vaudiau
  6. Aurélie Semervil
  7. Mathias Vetillard
  8. Aboubacar Sidiki K Coulibaly
  9. Natacha Jugniot
  10. Agathe Ok
  11. Mathilde Bausart
  12. Oriane Fiquet
  13. Marine Andrade
  14. Dicken Fardol
  15. Ikrame Haddar
  16. Zeina Abou Nader
  17. Judith Weber
  18. Hannah Theobald
  19. Matthieu Collin
  20. Joseph Calmette
  21. Giorgio Anselmi
  22. Flavia Fico
  23. Florent Ginhoux
  24. Laleh Majlessi
  25. Emmanuel L. Gautier
  26. Loredana Saveanu
  27. Julie Helft
  28. Marc Dalod
  29. Mathilde Dusseaux
  30. James P. Di Santo
  31. Stéphanie Hugues
  32. Pierre Guermonprez

Contributions

Conceptualization: S.H., P.G. Investigation: L.G., F.L.R.D.C., P.B., J.B., N.V., A.S., M.V., A.S.K.C., N.J., A.O., M.B., O.F., M.A., D.F., I.H., Z.A.N., J.W., H.T., G.A., F.F. Resources: F.G., L.M., E.L.G., L.S., J.H., MDalod, MDusseaux, J.P.D.S., S.H., P.G. Writing: L.G., F.L.R.D.C., S.H., P.G., Supervision: S.H., P.G. Funding acquisition: M.C., J.C., J.H., S.H., P.G.

Corresponding author

Correspondence to Pierre Guermonprez.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Communications thanks Moutih Rafei and the other anonymous reviewer(s) for their contribution to the peer review of this work. A peer review file is available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Source data

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gorline, L., do Carmo, F.L.R., Bourdely, P. et al. Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity. Nat Commun (2025). https://doi.org/10.1038/s41467-025-68018-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41467-025-68018-3